Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
February 15 2024 - 9:00AM
Business Wire
Pfizer Inc. (NYSE: PFE) invites investors and the general public
to access a live video webcast of its Oncology Innovation Day on
Thursday, February 29, 2024, from 1:00 p.m. EST to 5:30 p.m. EST,
with an approximately 20-minute break at the midpoint. During the
event, Pfizer Oncology leadership will provide details on the new
combined Pfizer Oncology Division, including its strategic
approach, robust portfolio, industry-leading R&D capabilities
and potential for growth through 2030 and beyond.
To access the live webcast and presentation slides, visit our
web site at www.pfizer.com/investors. Information on accessing and
registering for the webcast will be available at
www.pfizer.com/investors beginning today. Participants are advised
to register in advance.
Participants will also have an opportunity to submit questions
via the webcast, and selected questions will be answered during the
live Q&A sessions with leadership.
Participants who are unable to join the webcast from a computer
or mobile device can dial either 800-456-4352 in the United States
and Canada or 785-424-1086 outside of the United States and Canada.
The passcode is “91325”. This audio line is a “listen-only”
experience; questions cannot be submitted through the audio
line.
The transcript and webcast replay will be made available on our
web site at www.pfizer.com/investors within 24 hours after the end
of the live webcast and will be accessible for at least 90
days.
About Pfizer Oncology
At Pfizer Oncology, we are at the forefront of a new era in
cancer care. Our industry-leading portfolio and extensive pipeline
includes game-changing mechanisms of action to attack cancer from
multiple angles, including antibody-drug conjugates (ADCs), small
molecules, bispecifics and other immunotherapies. We are focused on
delivering transformative therapies in some of the world’s most
common cancers, including breast cancer, genitourinary cancer and
hematologic malignancies, as well as melanoma, gastrointestinal,
gynecological and thoracic cancers, which includes lung cancer.
Driven by science, we are committed to accelerating breakthroughs
to extend and improve patients’ lives.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 170 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
Disclosure Notice: The webcast may include
forward-looking statements about, among other things, our
anticipated operating and financial performance, including
financial guidance and projections; reorganizations; business
plans, strategy, goals and prospects; our Environmental, Social and
Governance (ESG) priorities, strategies and goals; Pfizer Oncology;
expectations for our product pipeline, in-line products and product
candidates, including anticipated regulatory submissions, data
read-outs, study starts, approvals, launches, clinical trial
results and other developing data, revenue contribution and
projections, potential pricing and reimbursement, potential market
dynamics, size and utilization rates, growth, performance, timing
of exclusivity and potential benefits; strategic reviews; capital
allocation objectives; dividends and share repurchases; plans for
and prospects of our acquisitions, dispositions and other business
development activities, and our ability to successfully capitalize
on growth opportunities; manufacturing and product supply; our
ongoing efforts to respond to COVID-19, including our COVID-19
products; our expectations regarding the impact of COVID-19 on our
business, operations and financial results; and other statements
about our business, operations and financial results, that are
subject to substantial risks and uncertainties that could cause
actual results to differ materially from those expressed or implied
by such statements. A description of these risks and uncertainties
can be found in Pfizer’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2022 and in its subsequent reports on Form
10-Q, including in the sections thereof captioned “Risk Factors”
and “Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
The forward-looking statements in the webcast speak only as of
the original date of the webcast. Pfizer assumes no obligation to
update forward-looking statements contained in the webcast as the
result of new information or future events or developments.
Category: Finance, Research
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240215326427/en/
Media Contact: PfizerMediaRelations@Pfizer.com +1 (212) 733-1226
Investor Contact: IR@Pfizer.com +1 (212) 733-4848
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2024 to May 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From May 2023 to May 2024